InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Comparison of the effects of CYT107 vs Placebo administered IM at 10μg/kg twice a week for
three weeks on immune reconstitution of lymphopenic COVID-19 patients
Phase:
Phase 2
Details
Lead Sponsor:
Revimmune
Collaborators:
Amarex Clinical Research Cancer Research Institute, New York City M.D. Anderson Cancer Center Memorial Sloan Kettering Cancer Center